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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Brain hexokinase, the first enzyme of the glycolytic 
pathway, catalyzes the phosphorylation of glucose using ATP 
as the phosphoryl donor (1,2). It is a crucial enzyme in the 
regulation of energy metabolism in the brain (1,2). The 
molecular mass of human brain hexokinase is about 100,000 
daltons, twice that of yeast hexokinase (3-7). The N- and C-
terminal halves are homologous to each other and to yeast 
hexokinase in the primary sequence (3-7), probably as a 
result of gene duplication and fusion. In 1989 White and 
Wilson (8) reported studies on the selective tryptic cleavage 
of rat hexokinase I into discrete N- and C-terminal halves. 
They found that the active site of the enzyme resides in the 
C-terminal half of hexokinase I. Their kinetic results 
suggest that the C-terminal portion of brain hexokinase, 
mini-hexokinase, is virtually identical to the intact enzyme. 
Recently, Magnani et al. (9) and our laboratory (10) obtained 
mini-hexokinase from human tissue by recombinant technology 
and, like White and Wilson (8), found that the truncated 
enzyme is very similar in kinetic properties to hximan 
hexokinase I. 
The kinetic mechanism of brain hexokinase is thought to 
be random Bi Bi (11-13), and a mechanism for its molecular 
regulation has been proposed (14,15). This enzyme is strongly 
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inhibited by glucose-6-P and this inhibition can be relieved 
by inorganic phosphate (Pi). This has been an attractive 
model for regulation of glycolysis in the brain. The de-
inhibition of hexokinase and stimulation of 
phophofructokinase by .Pi would cause .increased production and 
removal of glucose-6-P simultaneously, resulting in an 
increased glycolytic flux. 
The site of action glucose-6-P inhibition has been a 
subject of controversy for many years ever since 1954 when 
Crane and Sols (16) made their proposal for a separate site 
(other than the active site) on the enzyme. This proposal 
was based on the failure of glucose to reverse the inhibition 
and on the kinetically observed differences in the 
specificities for the binding of the glycosyl portions of 
glucose and glucose-6-P to the enzyme. Another proposal for 
an allosteric site was also attractive from an evolutionary 
view point. It has been suggested that the brain enzyme 
might have evolved by duplication and fusion of a gene coding 
for yeast hexokinase and by subsequent evolution of one of 
the two catalytic sites into a regulatory one (17,18). This 
model predicts the existence of two binding sites for 
glucose-6-P (active site and regulatory site) per molecule of 
the enzyme. However, in several binding studies, only one 
binding site for glucose-6-P has been detected (19-21). The 
finding of Fromm and coworkers, that glucose-6-P inhibition 
is competitive versus ATP (22), suggests that glucose-6-P 
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competes with the y-phosphate group of ATP at the nucleotide 
site on the enzyme. Further, they suggested that the hexose 
moiety of glucose-6-P might occupy an adjacent site within 
the active-site domain but outside its glucose subsite. 
The interaction of glucose-6-P and Pi has been 
studied by a number of methods. Kinetic studies on the 
Hexokinase I from a variety of sources have indicated that at 
physiological concentrations of Pi (3-5mM) Pi neither 
activates the uninhibited enzyme nor does it alter the K„ for 
ATP (23,24), however, it can relieve the inhibition by 
glucose-6-P. Direct binding studies of Pi to hexokinase 
suggests that l mole of Pi binds per mol of enzyme. The 
binding of Pi at low concentrations does not appear to be 
influenced by MgATP^" or glucose. On the other hand MgATP^" 
and glucose-6-P exhibit competitive binding (25). It seems 
that Pi and ATP function by different mechanisms in 
dissociating glucose-6-P from hexokinase. Those results 
suggest the Pi binding site is distinct from the active site. 
Wilson and his coworkers (26) have demonstrated that Pi binds 
to the N-terminal half of the enzyme on the basis of its 
ability to protect the N-terminal half against denaturation 
and proteolysis. The result from our lab supports this 
conclusion (10). The truncated hexokinase, mini-hexokinase, 
starting with Met-455 and ending at the C-terminus lost its 
ability to ameliorate inhibition of glucose-6-P-inhibited 
mini-hexokinase in the presence of phosphate. We suggest 
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that the Pi site either resides in the N-terminal half of 
hexokinase I or requires the N-terminal portion of the 
enzyme. Recently, Tsai and Wilson (27) constructed the 
chimeric hexokinase from the N- and C-terminal domains of the 
rat type I and type II isozymes. The chimeric hexokinase 
consists of either the N-terminal half of type I hexokinase 
fused with the C-terminal half of the type II isozyme or the 
inverse pair. The response of the chimeras to Pi was 
correlated with the origin of the N-terminal domain. This 
finding also supports the conclusion that the Pi binding 
site is in i:he N-terminal portion. 
The structure of yeast hexokinase has long been 
available (28-30), and has been used as a model for site-
specific mutagenesis studies of hexokinase. The glucose-
binding domain has been proposed from these investigations. 
Unfortunately, the crystal structure of the yeast enzyme 
provides no information on the ATP binding domain within the 
active site. In 1992, Bork et al. and others (31-33) 
suggested that the heat shock protein hsc70, actin, and yeast 
hexokinase may have similar three-dimensional structures in 
their ATP-binding sites. The ATP-binding motif is distinctly 
different from the single phosphate-binding loop in, for 
example, adenylate kinase, rec A protein, or ras p21 (34). 
Amino acid residues in the ATP-binding site are conserved 
although no overall sequence similarity among these three 
proteins is found. Those conserved residues are also found 
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in human brain hexokinase. 
The major work of this dissertation is to establish the 
ATP-binding site by molecular modelling and site-directed 
mutagenesis. An effort was devoted to the crystallization of 
human brain hexokinase. The Pi binding site was also 
studied. 
Dissertation Organization 
This dissertation is organized into six chapters. 
Chapter 1 provides the background of study, statement of the 
problems and objectives of the research project. Chapter 2 
to 5 present four papers that are either published or 
submitted to the scholarly journals. Chapter 2 reports 
construction of a vector to overexpress the truncated 
hexokinase, also studies the inorganic phosphate binding site 
and ATP binding site. Chapter 3 is devoted to the 
establishment of the -ATP-binding site model of human brain 
hexokinase. Chapter 4 further studies amino acid residues in 
the ATP binding site, especially the role of glycine residues 
in the catalytic reaction of human brain hexokinase. Chapter 
5 describes the crystallization of human brain hexokinase in 
order to resolve the three-dimensional structure of human 
brain hexokinase. Chapter 6 includes the concluding remarks 
and recommendations. 
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CHAPTER 2. ACTIVE SITE RESIDUES OF HUMAN BRAIN HEXOKINASE AS 
STUDIED BY SITE-SPECIFIC MUTAGENESIS^ 
A paper published in Journal of Biological Chemistry^ 
Chenbo Zeng^ and Herbert J.Fronim^'" 
Abstract 
The truncated gene of hexokinase, mini-hexokinase, 
starting with methionine*®® and ending at the C-terminus was 
expressed in Escherichia coli. Mini-hexokinasae lost its 
ability to ameliorate inhibition of glucose-6-P inhibited 
mini-hexokinase in the presence of phosphate (Pi). We 
suggest that the Pi site either resides in the N-terminal 
half of hexokinase I or requires the N-terminal portion of 
the enzyme. Site-directed mutagenesis was performed to 
obtain two mutants of mini-hexokinase: C606S, C628S. Both 
are thought to be associated with the active site of 
^This research was supported in part by Research Grants 
NS10546 from the National Institute of Health, United State 
Public Health Service, and Grant MCB-9218763 from the National 
Science Foundation. This is Journal Paper J-16213 of the Iowa 
Agriculture and Home Economics Experiment Station, Ames, 
Project 2575. 
^Reprinted with permission of J. Biol. Chem.. 1995, 270, 
10509-10513. 
^Graduate student and Professor, respectively. Department of 
Biochemistry and Biophysics, Iowa State University. Research 
conducted and manuscript written by Zeng with assistance from 
Fromm. 
•*To whom correspondence should be addressed. 
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hexokinase I. These mutants exhibited a 3-fold increase in Km 
for glucose, but no cliange in either the Km for ATP or the 
k„t* The circular dichroism spectra (CD) showed no 
differences among the wild-type or mutant enzymes. These 
results suggest that Cys606 and Cys628 are not involved in 
glucose binding directly. The putative ATP binding site of 
full-length human brain hexokinase may involve R539 and G679, 
and these residues were mutated to lie. For the mutant R539I, 
the k„tvalue decreased 114-fold relative to wild-type 
hexokinase, whereas the K, values for ATP and glucose changed 
only slightly. No ctaange was observed for the Ki value for 
l,5-Anhydroglucitol-6-phosphate. CD spectra showed only a 
slight change in secondary structure. For the mutant G679I, 
overexpressed hexokinase is insoluble. We suggest R539 is 
important for catalysis by stablizing the transition state 
product ADP-hexokinase. G679 is probably important for proper 
folding of the protein. 
Introduction 
Brain hexokinase, hexokinase I (ATP:D-hexose 6-
phosphotransferase,EC 2.7.1.1), is thought to be the 
pacemaker of glycolysis in brain tissue (1) and the 
erythrocyte (2). The cDNAs for hexokinases from a variety of 
tissues, including yeast (3,4), human kidney (5), rat brain 
(6), rat skeletal muscle (7), rat liver (8,9), and mouse 
hepatoma (10) have been cloned, and their complete amino acid 
11 
sequences have been deduced from the cloned cDNAs. The C-
terminal domains of mammalian hexokinases and their N-
terminal domains have overall similarities to each other and 
to yeast hexokinase, probably as a result of gene duplication 
and fusion (11-15). The crystal structure of yeast 
hexokinase is available (16,17), and the putative glucose 
binding domain has been suggested from these investigations 
(8,18). 
The involvement of a cysteinyl residue either in or near 
the active site of brain hexokinase (19-22) has been 
suggested. Swarup and Kendare were the first investigators 
to use N-(bromoacetyl)-D-glucosamine to covalently modify 
brain hexokinase (23). They demonstrated that two sulfhydryl 
residues are involved in covalent modification with 
concomitant enzyme inactivation; however,the enzyme could be 
protected against inactivation by either ATP or glucose. 
Recently, Schirch and Wilson (24) used this same protocol 
with rat brain hexokinase and obtained results similar to 
those reported by Swarup and Kenkare (23), and concluded that 
there was a single critical sulfhydryl based on the 
observation that modification of that sulfhydryl totally 
inactivated the enzyme. Later, in a subsequent study, they 
isolated and partially sequenced two peptides that are 
modified by N-(bromoacetyl)-D-glucosamine and that are 
protected against modification by either glucose or N-
acetylglucosamine (25). By locating these two peptides 
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within the tertiary structure of yeast hexokinase, based on 
the structure proposed by Steitz and coworkers (16,17), they 
found that these peptides are close to the binding site for 
glucose. Comparing the amino acid sequences between yeast 
hexokinase and the brain hexokinase peptides, they found no 
cystine residues corresponding to the peptides in question. 
Based on the proximity of the peptides to the glucose binding 
site and the analysis of sequence homology between yeast 
hexokinase and those peptides, they questioned the existence 
of a single critical sulfhydryl. To solve this problem 
directly, we mutated Cys606 and Cys628, which are located in 
those two peptides. Working with adenylosuccinate synthetase 
(26), we found a thiol residue to be essential when 
covalently modified with 5,5'-dithiobis (2-nitrobenzoic 
acid); however, site-specific mutagenesis of the specific 
cysteinyl residue in question revealed that the covalent 
modification caused inactivation through a steric effect, 
i.e., the enzyme could not fold into its native conformation 
after modification v/ith 5,5'-dithiobis (2-nitrobenzoic acid). 
In 1989 White and Wilson (27) reported studies on the 
selective tryptic cleavage of rat hexokinase I into discrete 
N- and C- terminal halves. They found that the active site 
of the enzyme resides in the C-terminal half of hexokinase I, 
and they suggested that the allosteric site for glucose-6-P 
is contained in the N-terminal segment of brain hexokinase. 
Their kinetic results suggest that the C-terminal portion of 
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brain hexokinase, mini-hexokinase,is virtually identical to 
the intact enzyme. Recently, Magnani et al. (28) obtained 
mini-hexokinase from human tissue by recombinant technology 
and, like White and Wilson (27), found that the truncated 
enzyme is very similar in kinetic properties to human 
hexokinase I. 
In the present study, we report the functional 
expression of human brain mini-hexokinase in Escherichia 
coli and its purification to homogeneity. Site-directed 
mutagenesis was performed to obtain two mutants of mini-
hexokinase, C606S and C628S, in order to evaluate the roles 
of these two cysteinyl residues in the hexokinase reaction. 
Although our laboratory has cloned and expressed full-length 
human brain hexokinase in E.coli. we chose to investigate 
mini-hexokinase to simplify interpretation of the site-
specific mutagenesis data and, in addition, to study the 
effects of inorganic phosphate (Pi) on glucose-6-P inhibited 
mini-hexokinase. 
Because the crystal structure of yeast hexokinase did 
not contain ATP, the location of this substrate has not been 
defined. On the other hand, in actin and hsp70 heat shock 
protein there is a binding site for ATP, and it has been 
suggested (29-31) that a similar ATP binding domain may exist 
on hexokinase. To test this hypothesis, we used the 
structures of hsp70 and actin as a model in an attempt to 
locate the nucleotide binding site on human brain hexokinase 
14 
by using the technique of site-directed mutagenesis. 
Experimental Procedures 
Materials—The pET-lld plasmid was obtained from 
Novagen. E.Coli strains BL21(DE3) and TG-1 cells were 
obtained from Amersham Corporation. Ncol and SphI were from 
New England Biolabs, and BamHI and T4 DNA ligase were from 
Promega. The oligonucleotide-directed in vitro mutagenesis 
system, version 2.1, was a product of Amersham Corporation. 
The magic minipreps DNA purification system, was a product of 
Promega. Oligonucleotide synthesis and nucleotide sequence 
analysis were done by the Iowa State University Nucleic Acid 
Facility. Ampicillin, DL-dithiothreitol (DTT)®, 
phenylmethylsulfonylfluride (PMSF), ATP, NADP, NADPH, 
glucose-l,6-bisphosphate (Glc-l,6-BP), 1,5-anhydro-D-
sorbitol, streptomycin, phosphoenolpyruvate, 
deoxyribonuclease I (DNasel), lactatedehydrogenase /pyruvate 
kinase, and lysozyme were products of Sigma. Isopropyl-6-D-
thiogalactopyranoside (IPTG) was purchased from Clontech. 
Bio-gel HT was obtained from Bio-Rad Laboratories. 
Expression of mini-hexokinase pET-lld-mHKI—The full 
length cDNA for the human brain hexokinase I has been cloned 
into the expression vector pET-lla in our laboratory (32). 
®The abbreviations used are; DTT, DL-Dithiothreitol; PMSF, 
phenylmethyl-sulfonylfluoride; IPTG, Isopropyl-B-D-
thiogalactopyranoside; Glu-1,6-BP, Glu-1,6-bisphosphate; 
G6P,glucose-6-phosphate; DNase I, Deoxyribonuclease I. 
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This full length cDNA clone was further digested with 
restriction enzyme Ncol and BamHI to obtain a 1399bp Ncol-
BamHI fragment, which encodes a truncated form of hexokinase 
starting from methionine-455 to the terminal amino acid. The 
NcoI-BamHI fragment was then purified and ligated into 
plasmid pET-lld, containing the bacteriophage T7 promoter, 
previously digested with Ncol and BamHI to generate the pET-
lld-mHKI clone. pET-lld-mHKI was transformed into E. Coli 
strain BL21 (DE3), a phage lambda lysogen containing the T7 
RNA polymerase gene under control of the lacUVS promoter. A 5 
ml pregrowth culture of the transformed strain in M9 medium, 
plus 40mg/L ampicillin and 4mg/L glucose, was grown overnight 
and then added to 500ml of the same medium. The culture was 
shaken at 37° C to early log phase (A6oo=0.4), and IPTG was 
then added to a final concentration of 0.4mM to induce the T7 
RNA polymerase gene. Cultures were shaken vigorously for an 
additional 24 to 40 hours at 20° C. 
Purification of mini-hexokinase and full-lenath 
hexokinase—Protein purification was performed essentially as 
described previously (32) with some modifications. Cells 
were harvested by centrifugation at 4000xg for 10 min and 
washed once with lOmM KPi, pH7.0. The resultant pellet was 
resuspended in 120ml 5mM KPi,pH7.0,containing ImM EDTA, 50mM 
glucose, ImM DTT,9% glycerol, lysozyme (2mg/mL), and ImM 
PMSF. The cell suspension was kept at 0° C for 1 hour and 
then sonicated four times for 20s at 40W. To the mixture. 
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600/il diluted DNAase (150/il lOmg/ial DNAase stock +650ul IM 
MgCla) was added, and the suspension was incubated at room 
temperature for 20min. The lysate was centrifuged at 17500 
xg for 45min. The supernatant fluid was purified further by 
streptomycin, (NH4)2S04 precipitation, heating, and an ion-
exchange HPLC column step as described elsewhere (32). The 
concentrated fractions with high enzyme activity were then 
loaded onto a hydroxyapatite (HT) column (lx25cm) previously 
equilibrated with 25mMK, pH7.0 ,containing ImM DTT. A 
linear 360-ml gradient from 25mM to 0.5M KPi was used to 
eliate mini-hexokinase. The fractions with high enzyme 
activity were pooled, concentrated, and then injected onto 
Bio-Sil SEC gel-filtration HPLC columns (600mm x 7.5mm and 
300mm X 7.5mm connected together). Hexokinase activity was 
eluted with 50mM KP^ buffer, pH 7.0, containing O.IM KCl and 
1 mM DTT. 
Site-directed mutagenesis—Mutagenesis was performed by 
following the instructions provided with the 
oligonucleotide-directed in vitro mutagenesis system version 
2.1 from Amersham. The oligonucleotides used for mutagenesis 
are as follows; 
5—ACC-AAT-TTC-ATT-GTG-CTG-CTG-3 for R539I, 
5—CTC-ATT-GTT-ATT-ACC-GGC-AGC-3 for G679I, 
5—TCA-TTT-CCC-TCC-CAG-CAG-ACG-3 for C606S, 
5—GCA-ACA-GAC-TCC-GTG-GGC-CAC-3 for C628S, 
where the underlines represent the mutated bases. The DNA 
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sequence of the mutated gene was verified by DNA sequencing 
using the chain termination method (33). After mutagenesis, 
the BamHI-Sph I fragment of the mini-hexokinase gene was 
cloned back into the expression vector pET-lld, similarly 
digested with BamHI and SphI, and the BamHI-BamHI fragment of 
full-length hexokinase was cloned back into the expression 
vector pET-lla, which is also digested with BamHI, creating 
pET-lld-C606S, pET-lld-C628S, pET-lla-R539I, and pET-lla-
G679I, 
Hexokinase activity assay—Hexokinase activity was 
determined spectrophotometrically as described previously 
(32). 
Preparation of 1.5-An-G6P—l,5-An-G6P was prepared as 
described previously (34). 
Determination of protein concentration—Protein 
concentration was determined by the method of Bradford (35), 
using bovine serum albumin as a standard. 
Circular Dichroism Measurements—Circular Dichroism (CD) 
spectra were recorded under the supervision of Dr. E. 
Stellwagon at the University of Iowa. Measurements were made 
at room temperature in a 0.1 cm pathlength cylindrical quarts 
cell. The concentration of the sample was 0.15-0.66mg/ml in 
2mM Hepes,PH7.0, containing 20mM KCl and 0.2mM 
mercaptoethanol. Base lines were obtained using protein-free 
buffer solution. 
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Results 
Expression.purification. and characterization of wild-
tvpe mini-hexokinase—E.coli strain BL21:DE3 (pET-mHKI) 
expresses a 50KDa protein upon induction with IPTG. Mini-
hexokinase was purified from induced E.coli containing pET-
lld-mHKI to near homogeneity as described in "Experimental 
Procedures" using SDS-PAGE as the criterion (data not shown). 
The specific activity of mini-hexokinase is 62, which is 
close to the value for full-length hexokinase from human 
brain tissue (32). The K„ values of the substrates were 
determined to be 26iiK and 2.9mM for glucose and ATP, 
respectively. Mini-hexokinase is inhibited competitively 
relative to MgATP by glucose-l,6-bisphosphate (Fig. 2.1). A 
cardinal feature of glucose-6-P-inhibited hexokinase I is the 
ability of Pi to reverse the inhibitory effects of the 
product (36,37). Experiments of glucose-6-P inhibition and 
deinhibition by Pj were carried out to determine the effect 
of Pi on the glucose-6-P-inhibited mini-hexokinase. The 
results indicated that mini-hexokinase is sensitive to 
inhibition by glucose-6-P, but 6 mM P^ cannot relieve the 
inhibition caused by glucose-6-P. P^ at 6mM has little effect 
on mini-hexokinase in the absence of glucose-6-P (Fig. 2.2B). 
For full-length hexokinase I, Pi at 6mM does ameliorate 
glucose-6-P inhibition (Fig. 2.2A) (32,38). Therefore, we 
suggest that either the P^ site resides in the N-terminal 
half of hexokinase I, or that the N-terminal half of 
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Fig. 2.1. Inhibition of hexokinase I by glucose-1,6-
bisphosphate. Fig. 2.1A, full length hexokinase I; Fig. 
2.IB, mini-hexokinase. The concentration of glucose-1,6-
bisphosphate was OpiMC), 100/iM(+), 167/iM(A). Activity was 
determined using the glucose-6-phosphate dehydrogenase 
coupled assay. The measured change in absorbance per min was 
plotted as percentage of the enzyme activity at saturating 
concentrations of glucose and MgATP. The apparent Kj 
values for both mini-hexokinase and full length hexokinase 
I is lOO^M. 
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Fig. 2.2. Effectiveness of inorganic phosphate on 
reversing inhibition by l,5-An-G6P. Fig. 2.2A, full-length 
hexokinase I; Fig. 2.2B, mini-hexokinase. Concentration of 
glucose was 2 mM. Concentration of l,5-An-G6P and Pi were; 
(•), 0, 0; ( + ), 50mM, 0; (A), 50 /iM, 6 inM, respectively. 
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hexokinase I is required for deinhibition of glucose-6-P-
inhibited hexokinase I. 
Site-directed mutations of Ara539|, G1y679 in the 
putative ATP-bindina site—It has been reported that yeast 
hexokinase, actin, and hsp70 heat shock proteins have similar 
three-dimensional structures in their ATP binding sites, and 
in addition, the amino acid residues are conserved in the ATP 
binding sites (29-31). Based on this suggestion, R539 and 
G679 of human brain hexokinase might be involved in ATP 
binding. The R539 and G679 residues were mutated to lie by 
site-directed mutagenesis. Two mutants, D539I and G679I, were 
created by site-directed mutagenesis. The mutant D539I was 
purified to homogeneity and characterized kinetically (Table 
2.1). The keat value decreased 114-fold,the K„ value for ATP 
increased 2-fold, and the K„ value for glucose decreased 4.6-
fold. Little change was observed for the Ki values for 1,5-
An-G6P. For the mutant G679I, overexpressed hexokinase is 
insoluble. SDS PAGE indicated that mutant G679I hexokinase 
was overexpressed, but the cell extract did not contain 
hexokinase (data not shown). The G679 residue is probably 
important for proper folding of the protein. 
Site-directed mutations of Cys606. Cvs628 in the 
putative alucose-bindina site—Two mutants of mini-hexokinase 
were prepared to investigate whether Cys606 and Cys628 are 
involved in glucose binding and/or catalysis. Both mutants, 
C606S and C628S, exhibit 3-fold increases in K„ values for 
Table 2.1. A Comparison of the Kinetic data of the wild-type and the mutant forms of 
hexokinase 
K^(Glu) K„(ATP) K,(l,5-An-G6P) 
Hexokinase (/xM) (mM) (iM) (s'^) 
full-length wild-type 56 ±5.6 1.0±0.2 26 ±4.8 26.9 
full-length Arg539Ile 12 ± 3.2 1.9 ± 0.3 49 ± 11 0.23 
mini wild-type 26 ±4.0 2.9±0.3 22 ±2.5 17.1 
mini Cys606Ser 87 ±9.1 2.2±0.4 18.6 
mini Cys628Ser 89 ± 15 2.1 + 0.4 15.6 
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glucose compared with wild-type mini-hexokinase; however, no 
alteration was observed on the K„ for ATP (Table 2.1). In 
addition, both mutants are similar to wild-type mini-
hexokinase in enzyme activity. The CD spectra for mutants 
C606S and C528S and wild-type mini-hexokinase show no 
differences (data not shown). These results suggest that 
Cys606 and Cys628 are not involved in catalysis and that 
covalent modification of Cys606 and Cys628 by N-
(bromoacety1)-D-glucosamine very probably caused inactivation 
by disrupting the native conformation of brain hexokinase. 
Effect of mutations on the CD Spectra of Tninl-hexokinase 
and full length hexokinase—To check whether the change in 
K, values of mutants is due to gross structural 
perturbations, CD experiments were carried out for the wild-
type enzyme, mini-hexokinase, and the mutants C606S, C628S, 
and R539I. C606S and C628S mutants exhibit no differences in 
their CD spectra compared to that of the wild-type mini-
hexokinase (data not shown). These results suggest that the 
mutant amino acid residues at Cys606 and Cys628 do not 
cause changes in secondary structure. R539I and wild-type 
hexokinase showed only a slight difference in CD spectra 
(Fig. 2.3). 
Discussion 
The finding by White and Wilson (27) that brain 
hexokinase could be cleaved into two roughly equal segments 
i 
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Fig. 2.3. CD spectra for wild-type hexokinase 1(B) and 
mutant D539I(A). The concentration of the sample was 
adjusted to 660^g/ml. 
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of which the C- half is very similar, if not identical in 
properties to the native enzyme is extremely interesting. 
This observation is fully consistent with the suggestion that 
hexokinase I arose through gene duplication and fusion (il­
ls). Our studies with recombinant mini-hexokinase differ 
from those of the Italian group (28) only in the system used 
to express the enzyme. When we tested glucose-6-P-inhibited 
mini-hexokinase with levels of Pj known to deinhibit glucose-
6-P-inhibited full-length hexokinase (32,38), 6inM, no 
deinhibition was observed. We conclude, therefore, that the 
allosteric Pj site proposed for brain hexokinase (39) either 
resides in the N-terminal half of hexokinase I or requires 
that portion of the molecule for expression. However, White 
and Wilson (27) claimed that Pi ameliorates the inhibition of 
mini-hexokinase by l,5-An-G6P. The reason that our results 
are different from Wilson's findings is not clear. The 
observation that mini-hexokinase exhibits a 3-fold increase 
in K„ for ATP compared with the full-length enzyme suggests 
that the truncated and native enzymes exhibit somewhat 
different kinetic properties, e.g., the N-terminal region of 
hexokinase I may be required for maintaining the proper 
conformation of the active site. 
In 1962 we found that glucose-6-P is a normal competitive 
product inhibitor of ATP in the brain hexokinase reaction 
(40). This finding was clearly at variance with data from 
the laboratory of Crane and Sols (41). It is now wildly 
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accepted that glucose-6-P is indeed a competitive inhibitor 
of ATP (28,40,42,43). Although we suggested that glucose-6-P 
is a normal product inhibitor of brain hexokinase, 
others,notably Lazo et al. (44) and Wilson (45), have 
maintained that glucose-6-P binds at an allosteric site on 
hexokinase I. Reports from our laboratory, based primarily 
on kinetic studies (40), as well as NMR experiments from 
other laboratories (46,47), are clearly at variance with the 
notion that a topologically distinct site for glucose-6-P 
exists on hexokinase I. In addition, initial rate studies 
from Sols laljoratory (48) as well as ours (49) on the back 
reaction clearly eliminate the existence of a high affinity 
glucose-6-P inhibitory allosteric site. The finding by White 
and Wilson (27) that mini-hexokinase is as susceptible to 
glucose-6-P inhibition, both quantitatively and 
qualitatively, as the native brain enzyme is fully consistent 
with the proposition that an allosteric site for the sugar 
phosphate product does not exist. What is clear from the 
present report is that the allosteric site for Pi on 
hexokinase I is in some way associated with the N-terminal 
half of the enzyme. 
In 1992, Bork et al.and others (29-31) indicated that 
the heat shock protein hsp70, actin, and yeast hexokinase 
have similar three- dimensional structures in their ATP 
binding sites. The ATP binding site consists of five motifs: 
PHOSPHATE 1, CONNECT 1, PHOSPHATE 2, ADENOSINE, and CONNECT 
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2. The ATP binding motif is distinctly different from the 
single phosphate binding loop in, for example, adenylate 
kinase, rec A protein, or ras p21 (50). Amino acid residues 
in the ATP binding site are conserved although no overall 
sequence similarity among these three proteins is found. In 
particular, the PHOSPHATE 1 motif, which interacts with the 
6- and yphosphates of the nucleotide, shows sequence 
similarity. In this motif, positively charged lysine or 
arginine residues form a salt bridge to the negataively 
charged nucleotide phosphates. In brain hexokinase, the 
corresponding residue is Arg539. In this report Arg539 was 
mutated to lie. The k<.at value for the mutant decreased 114-
fold relative to the wild-type enzyme. The K„ value for ATP 
increased 2-fold, whereas the K. value for glucose decreased 
4.6-fold. No change was observed for the Ki value for 1,5-An-
G6P. CD spectra showed only a minor change in secondary 
structure. We suggest therefore that Arg539 is important 
for catalysis. Since the currently available yeast hexokinase 
structure (51) does not provide for an ATP site, we used 
actin as a model for the ATP binding site. In actin the 
residue corresponding to Arg539 is Lysl8 (29-31). The e-amino 
group interacts with the side chain carboxylate group of 
Aspll, which binds to the metal ion. In the ADP-actin 
complex, the e-amino group forms hydrogen bonds with the a-
and B-phosphates. We suggest by analogy to actin that Arg539 
is important for catalysis by stabilizing the transition 
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state product ADP-hexokinase complex. In the motif PHOSPHATE 
2, instead of the conserved Aspl54 of actin/hsc70 in which 
Aspl54 binds the metal ion, brain hexokinase has Gly679. When 
Gly679 was mutated to lie, the overexpressed mutant, G679I, 
was found to be insoluble. It is possible that G679I is 
overexpressed in the form of inclusion bodies. We suggest 
that G679 is probably important for the proper folding of the 
protein. 
A number of studies have shown that there is an 
essential thiol group at the active site of hexokinase I (22-
24). Schrich and Wilson (25) isolated three peptides 
containing modified sulfhydryl groups after trypsin digestion 
of the enzyme. They found that labelling of two peptides, 
one containing Cys606 and the other, Cys628, was sensitive to 
the addition of protective ligands, glucose or N-
acetylglucosamine. One explanation for this observation is 
that sulfhydryl groups are important for activity, contrary 
to the previous conclusion that only one sulfhydryl group is 
critical. Another explanation is that neither sulfhydryl 
group is important; however, modification of either 
sulfhydryl by a large molecule, e.g., GlcNBrAc, will hinder 
the binding of glucose. To determine the importance of 
Cys606 and Cys628, Cys residues were mutated to Ser at these 
two positions. Both of these mutants exhibited 3-fold 
increase in K„ values for glucose, but no change in either 
the K„ for ATP or the k^at was observed. These results 
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suggested that Cys606 and Cys628 are not critical residues 
for either catalysis or binding of substrates. Amino acid 
sequence comparisons between yeast hexokinases A and B and 
brain hexokinase type I show no corresponding Cys residues 
in yeast hexokinase, which also implies that these two Cys 
residues might not be important in the functioning of 
hexokinase I. According to X-ray diffraction studies of 
yeast hexokinase (16,17), Cys606 and Cys628 are located at 
or near the glucose-binding site. Their modification with 
big molecules may hinder the entrance of the substrate and 
lead to the loss of activity. Results of the current 
investigation suggest that the X-ray diffraction 
crystallographic structure of the ATP binding sites of actin 
and hsp70 (29-31) are excellent models for the ATP binding 
site of human brain hexokinase based upon site-specific 
mutagenesis and kinetic studies. 
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CHAPTER 3. THE ATP-BINDING SITE OF HUMAN BRAIN HEXOKINASE AS 
STUDIED BY MOLECULAR MODELING AND SITE-DIRECTED MUTAGENESIS^ 
A paper submitted to Biochemistry 
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Abstract 
The ATP binding site within the active site of brain 
hexokinase is unknown since the crystal structure of the 
hexokinase-ATP complex is unavailable. It was found that the 
ATP binding site of brain hexokinase is homologous to that of 
actin, heat shock protein hsc70, and glycerol kinase. Based 
upon these similarities, the catalytic domain of human brain 
hexokinase was modeled and the putative ATP-binding site was 
proposed. Site-directed mutagenesis was performed in the 
putative ATP-binding site to test the proposed model. 
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Asp532, which is thought to be involved in the interaction 
with the ion of the MgATP^" complex, was mutated to Lys 
and Glu. The k^at values decreased 1000-fold and 200-fold, 
respectively for the two mutants. Another residue, Thr680 
was proposed to interact with the y-phosphoryl group of ATP 
through hydrogen bonds, and was mutated to Val and Ser. The 
kcat value of the Thr680Val mutant decreased 2000-fold whereas 
the kcat value of the Thr680Ser decreased only 2.5-fold, 
implying the importance of the hydroxyl group. The K„ values 
for either ATP or glucose of all the above mutants showed 
little or no change relative to the wild-type enzyme. The 
values for the glucose-6-P analogue, l,5-anhydroglucitol-6-P, 
were the same as that of the wild-type enzyme, and the 
inhibition was reversed by inorganic phosphate (Pi) for all 
four mutants. The circular dichroism spectra of the mutants 
were the same as that of the wild-type enzyme. The results 
from the site-directed mutagenesis studies serve to support 
the molecular model proposed for the ATP-binding site in 
human brain hexokinase. 
Introduction 
Hexokinase I, brain hexokinase, is one of four 
hexokinase isozymes found in mammalian tissue (Katzen & 
Schimke, 1965). It is believed to be the "pacemaker" of 
glycolysis in brain tissue and the red blood cell (Lowry & 
Passonneau, 1964; Rapoport, 1968). The kinetic mechanism of 
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brain hexokinase is thought to be random bi bi (Ning et al., 
1969; Bachelard et al., 1971; Gerber et al., 1974), and a 
mechanism for its molecular regulation has been proposed 
(Ellison et al., 1975; Fromra, 1981; Wilson, 1984). Brain 
hexokinase exhibits regulatory properties that are unique 
among the isozymes of hexokinase, i.e., it is potently 
inhibited by its reaction product glucose-6-P, and this 
inhibition can be reversed by physiological levels of 
inorganic orthophosphate (Pi) (Rudolph & Fromm, 1971; Fromm, 
1981; Ureta, 1975). Brain hexokinase consists of two 
structural domains homologous to each other with about 50% 
identity and to yeast hexokinase with about 30% identity 
(Nishi et al., 1988). The catalytic properties of brain 
hexokinase are associated with the C-terminal domain, while 
the N-terminal domain is thought to be involved in molecular 
regulation (Nishi et al., 1988). 
The structures of different crystal forms of the o: and 
6 isozymes of yeast hexokinase were investigated by Steitz 
and his collaborators (Anderson et al.,1978; Bennett et al., 
1980; Harrison, 1985). They discovered that binding of 
glucose causes significant conformational changes in 
hexokinase which narrows ("closes") the active site cleft of 
the enzyme (Bennett et al., 1978). The published structures 
of hexokinase b complexed with ortho-toluoylglucoseamine, and 
hexokinase a complexed with glucose represent open and closed 
conformations of the enzyme (Anderson et al.,1978; Bennett et 
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al., 1980; Harrison, 1985). In 1994 the computer generated 
model for a mammalian hexokinase isozyme, glucokinase, 
complexed with glucose was also published (Charles et al. 
1994). In spite of success in understanding the interaction 
of hexokinase with glucose, the interaction of the enzyme 
with ATP is still unclear. Steitz and collaborators have 
attempted to model ATP in the active site of the enzyme, 
based on the crystal structure of open hexokinase b soaked 
with 8-bromoadenosine monophosphate (Shoham & Steitz, 1980). 
The authors suggested that ATP may be bound nonspecifically 
to the open hexokinase form because the binding site for the 
phosphate part of the ligand seemed to form during the 
conformational transformation of the enzyme from the open to 
the closed state (Shoham & Steitz, 1980). Our study 
represents the first attempt to model ATP within the active 
site of mammalian hexokinase in its closed form. 
Recently, it was reported that yeast hexokinase, 
glycerol kinase, actin and heat shock protein hsc70 have 
similar ATP-binding domain structures although there are no 
overall primary sequence similarities among them (Bork et 
al., 1992; Kabsch et al., 1990; Flaherty et al.,1991; Kabsch 
& Holmes, 1995). This discovery suggests an alternative 
approach for modeling ATP in the active site of hexokinase, 
namely, by superimposing the homologous ATP-containing 
structures on hexokinase. The model obtained using this 
approach for the interaction of the C-terminal domain of 
38 
brain hexokinase with ATP pinpointed the putative ATP-binding 
residues. This paper presents kinetic studies on some 
mutants of the presumed ATP-binding residues. Our results 
provide strong support for our ATP-binding site model of 
human brain hexokinase. 
Experimental Procedures 
Materials—Affi-Gel Blue Gel and Bio-gel hydroxyapatite 
were obtained from Bio-Rad Laboratories. Transformer™ Site-
Directed Mutagenesis Kit (2nd version) was a product of 
Clontech. The Magic Minipreps DNA purification system was a 
product of Promega. Oligonucleotide synthesis and nucleotide 
sequence analysis were done by the Iowa State University 
Nucleic Acid Facility. Nru I was from New England Biolabs. 
Xho I was from Promega. The pET-lla plasmid was obtained 
from Novagen. Escherichia coli strains BL21(DE3) and TG-1 
cells were obtained from Amersham Corp. Ampicillin, 
phenylmethylsulfonyl fluoride (PMSF)®, ATP, NADP, NADPH, 
glucose-1,6-bisphosphate (Glu-l,6-BP), deoxyribonuclease I 
(DNase I), Isopropyl-l-thio-6-D-galactopyranoside (IPTG), and 
1,5-anhydro-D-sorbitol were products of Sigma. 
Modeling the brain hexokinase complexed with ATP and 
jIg2+_The alignment of the sequences was made by analogy with 
®The abbreviations used are: PMSF, phenylmethyl-
sulfonylfluoride; IPTG, Isopropyl-B-D-thiogalactopyranoside; Glu-
1,6-BP, Glu-1,6-bisphosphate; Glucose-6-P,glucose-6-phosphate; 1,5-
an-G6P, 1,5-anhydroglucitol-6-phosphate. 
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the structure-based alignment of human glucokinase and yeast 
hexokinase B reported earlier (Charles et al., 1994). The 
program AMMP was used to build the models (Harrison, 1993). 
The force field was the sp3 variation of the UFP potential 
set (Harrison, 1993; Rappe et al., 1992). The amortized fast 
multipole algorithm was used for the non-bonded and 
electrostatic terms and no cut off radius was applied. 
Crystallographically ordered solvent from yeast hexokinase 
was included. The open form was modelled by fixing the 
conserved atoms at their observed positions and building the 
remainder of the structure. Then the whole structure was 
minimized. A homotopy method (Harrison, 1995) was used to 
minimize the structures. In the homotopy method the targets 
for the minimization are gradually shifted from the current 
erroneous positions to the desired targets. The steps are 
controlled by a critical path parameter A. which is slowly 
varied from 1 to 0. The homotopy was applied to the bonds 
and angle terms with the pyramid height torsion and non-
bonded terms always being minimized. The path was tracked by 
minimization which approximates tracking a zero in the first 
derivative of the energy. Conjugate gradient minimization 
was used. The structure was minimized in two passes where 
the tracking parameter X was varied form 0.95 to 0 in 20 
steps of 0.05. Procheck (Laskowshi et al., 1993) was used to 
check the stereochemistry at the end of the process and no 
significant errors were found. 
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The closed form of hexokinase was initially modelled in 
the same manner, but starting from the yeast hexokinase A 
coordinate set. There is a region in one of the helices in 
the small domain of yeast hexokinase A which was poorly 
determined in the electron density (Harrison, 1985). When 
the model in that region was examined, it was found to be 
unsatisfactory, e.g., hydrophilic amino acids such as 
arginine were pointing into the domain and hydrophobic acids 
such as tyrosine or phenylalanine were pointing out into the 
solvent. The stereochemistry in that region was also poor. 
Therefore, it was decided to model the closed structure by 
using the yeast coordinates as guides for the backbone and 
deforming the open structure into the closed form. The same 
homotopy method was used with the homotopy applied to the a 
carbon restraints as well as the bonds and angles. The two 
modelled structures were similar in the small domain except 
where the poorly defined region was, and in that region the 
new model was much more consistent with the expected 
distribution of amino acid side chain positions. 
The initial positions and conformations of MgATP^" 
complexes in the active site of brain hexokinase were 
obtained by superimposing the conserved residues of the ATP 
binding site of the enzyme (Bork et al., 1992)) and the 
corresponding residues of either actin, heat shock protein, 
or glycerol kinase complexed with ligands (PDB entries are 
lATN, INGJ, IGLC, respectively). The model of the complexes 
41 
of the closed form of brain hexokinase and ATP, which were 
built either from the ADP complexes of glycerol kinase or 
from the ATP complexes of actin, were further energy 
minimized with the same AMMP program. 
Expression of the Wild Type and Mutant Human Brain 
Hexokinase I—The cDNA for human brain hexokinase I has been 
cloned into the expression vector pET-lla to generate pET-
lla-HKI in our laboratory (Liu et al., 1991). pET-lla-HKI 
was transformed into E. Coli strain BL21(DE3), a phage k-
lysogen containing the T7 RNA polymerase gene under control 
of the lacUVS promoter. A 5-inL pregrowth culture of the 
transformed strain in M9 medium plus 40 mg/L ampicillin, 1 mM 
MgS04 and 4mg/L glucose was grown overnight and then added to 
500 ml of the same medium. The culture was shaken at 37° C 
to early log phase (A6oo=0.4), and IPTG was then added to a 
final concentration of 0.4 mM to induce the T7 RNA polymerase 
gene. Cultures were shaken vigorously for an additional 24 
hours at 22° C. 
Purification of the Wild Type and Mutant Forms of Human 
Brain Hexokinase I—The cells containing the overexpressed 
hexokinase were collected by centrifugation. About 30-gram 
wet cells (~30 mL) were suspended in a 30-mL of suspension 
solution containing 50 mM Tris-HCl (pH8.0)-10 mM glucose-0.5 
jmM EDTA-lmM mercaptoethanol-2 mM PMSF. The cells were broken 
by French Press at a pressure of lOOOpsi. This procedure was 
repeated twice. 0.9-mL of DNasel solution (0.15-mL 10 mg/mL 
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DNasel stock plus 0.65-inL 1 M MgCl2) was mixed with the 
broken cells for 30 minutes. The broken cell suspension was 
subjected to centrifugation for 50 minutes at 12,000 rpm. 
The supernatant fluid was dialyzed against 2 L of the 
dialysis buffer containing 50 mM Tris-HCl (pH7.0)-10 mM 
glucose-0.5 mM EDTA-1 mM mercaptoethanol. The buffer was 
changed twice. The dialyzed cell extract was loaded onto a 
X 13 cm Affi-Gel Blue Gel column (Wilson,1989) and washed 
with the same solution that was used for dialysis. The 
column was further washed with the buffer having the above 
composition tut at pH 8.0, and then with the bufter 
containing 50 mM Tris-HCl (pH 9.0)-10 mM glucose-0.5 mM EDTA 
1 mM mercaptoethanol-20% (v/v) glycerol. Human brain 
hexokinase I was eluted with 1.5 mM glucose-6-P in the same 
pH 9.0 buffer. The fractions containing human brain 
hexokinase were identified by SDS-polyacrylamide gel 
electrophoresis, pooled and subjected to ultrafiltration. 
5-10 ml of concentrated enzyme solution was loaded onto a 1 
30 cm Bio-gel hydroxyapatite column equilibrated with buffer 
containing 25 mM KPi-1 mM mercaptoethanol. The protein was 
eluted with 180 mL of a linear gradient solution of low 
ionic strength buffer containing 25 mM KPi-1 mM 
mercaptoethanol and 180 mL of high ionic strength buffer 
containing 0.3 M KPi-1 mM mercaptoethanol. The fractions 
containing pure human brain hexokinase were identified by 
SDS-polyacrylamide electrophoresis, collected, concentrated. 
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and stored in 50% (v/v) glycerol at -20" C. 
Site-directed Mutagenesis—Mutagenesis was performed by 
following the instructions provided with Tansformer™ Site-
Directed Mutagenesis Kit (2nd version) from Clontech. The 
oligonucleotides used for mutagenesis are as follows: 5'-
TTCTTGGCCCTGAAGCTTGGAGGAAC-3' for Asp532Lys, 5'-
GCCCTGGAACTTGGAGG-3' for Asp532Glu, 5'-TTGTTGGGGTCGGCAGCAATG-
3' for Thr680Val, and 5'-TTGTTGGGTCCGGCAGCAATG-3' for 
Thr680Ser, where the underlines represent the mutated bases. 
The selective oligonucleotide sequence was chosen at the Nrul 
restriction site in the vector pET-lla and designed to change 
the Nrul site to a Xhol site. The sequence of the selective 
oligonucleotide is 5^-CAGCCTCGCCTCGAGAACGCCAG-3^. where the 
underline represents the Xhol site. The DNA sequence of the 
mutated gene was verified by DNA sequencing using the method 
of fluorescent dideoxychain termination sequencing. 
Hexokinase Assay—Hexokinase activity was determined 
spectrophotometrically as described previously (Liu et al., 
1991). For kinetic characterization, the amount of the wild-
type and mutant human brain hexokinase was adjusted to give 
an activity of approximately 5 x lO"^ AODs^o/roin. Human brain 
hexokinase enzyme was dialyzed against a solution containing 
50 mM Tris-HCl (pH 7.0)-lmM mercaptoethanol to remove Pi. 
Glucose-6-phosphate dehydrogenase was dialyzed against the 
same solution to remove (NH4)2S04. Since glucose-6-phosphate 
dehydrogenase can use glucose as its substrate at high levels 
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of the sugar, the amount of glucose-6-phosphate dehydrogenase 
used was as small as possible in order to preclude glucose 
oxidation. 0.1 unit of glucose-6-phosphate dehydrogenase was 
used in 1-ml of the assay system. 
Preparation of 1.5-an-G6P—1.5-an-G6P was prepared as 
described previously (Ferrari et al., 1959). 
Determination of Protein Concentration—Protein 
concentration was determined by the method of Bradford 
(Bradford, 1976), using bovine serum albumin as a standard. 
Circular Dichroism Measurement—Circular Dichroism (CD) 
spectra were recorded using a Jasco J710 CD spectrometer as 
described previously (Zeng & Fromm, 1995). 
Results and Discussion 
Purification of wild-type and Mutant Human Brain 
Hexokinase—The purification procedure outlined in this report 
is greatly simplified relative to previously reported methods 
(Zeng & Fromm, 1995) and the enzyme yield is increased (20-
30%). Approximately, 20 mg of pure enzyme can be obtained 
from 10 liters of E. coli culture. The procedure requires 
only two columns (Affi-Gel Blue Gel and Bio-Gel 
hydroxyapatite), dialysis and ultrafiltration. Fig. 3.1 
shows the SDS-PAGE at each step of purification. The mutant 
enzymes, Asp532Lys, Asp532Glu, Thr680Val, and Thr680Ser, bind 
to the Affi-Gel Blue-Gel column, implying that their ATP 
binding ability is retained after mutagenesis. 
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Modeled interaction of brain hexokinase with ATP and 
Mg2i—The sequence alignment of the catalytic domain of human 
hexokinase with yeast hexokinase isomers A and B revealed 31% 
and 33% identity, respectively. The homology is especially 
high in the elements of secondary structure and in the 
regions of interactions with substrates (Fig. 3.2). The 
model of the closed form of brain hexokinase, which was built 
from its open form by bending to yeast hexokinase A, is as 
similar to the prototype structure as the model built 
directly from hexokinase A; however, the geometry of its 
small lobe (Fig. 3.3) is significantly improved. 
Our modeling of the ternary complex of brain hexokinase 
was based on the assumption that the position of ATP and Mg^* 
relative to the conservative residues of the active site 
must be consistent in all homologous phosphotransferases. The 
crystal structures of glycerol kinase ligated with ADP and 
Mg^^ (Hurley et al., 1993), the ATP-binding domain of actin 
ligated with ATP and Ca®"^ (Kabsch et al., 1990), and the ATP-
binding domain of heat shock protein ligated with ANP (5'-
adenylyl-B,y-imidodiphosphate) and Mg^"^ (Flaherty et al., 
1994) (Protein Data Base entries are IGLC, lATN, INGJ, 
respectively) were used for modeling. The superimposition of 
these enzymes on the model of the closed form of the 
catalytic domain of brain hexokinase demonstrated that all 
three ATP and Mg^"^ analogues have similar positions in the 
active site of brain hexokinase (Fig. 3.4). ADP from 
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Fig. 3.1. SDS PAGE patterns for each step of the 
purification of wild-type human brain hexokinase. Lane 2, 
cell-free extract, lane 3, the enzyme fraction after the 
Affi-Gel Blue Gel column, and lane 4, the enzyme fraction 
after the Bio-Gel hydroxyapatite column. Lanes 1 and 5, 
protein standards; the molecular masses for the bands a, 
c, d, and e are 200, 116, 97.4, 66.2, and 45 kDa, 
respectively. 
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Fig. 3.2. Structural alignment of amino acid sequences 
of the catalytic domain of human brain hexokinase and yeast 
hexokinases A and B. The residues mutually identical with 
those of brain hexokinase are outlined in black, and 
homologous residues are in shaded boxes. The elements of 
secondary structure are from the crystal structure of yeast 
hexokinase B. G, P, R, and A on the top of the brain 
hexokinase sequence indicate residues forming the binding 
sites for glucose, phosphates, ribose, and adenine, 
respectively. The picture was prepared using 
ALSCRIPT(Barton, 1993). 
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Fig. 3.3. Stereoview of the Co backbone of the modelled 
structure of the catalytic domain of brain hexokinase. The 
domain has a closed form. ATP, glucose, and Mg^"^ ion bound 
in the cleft are shown with bold lines. The conservative 
residues within phosphotransferases are shown with filled 
circles. 
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glycerol kinase is shifted approximately 2.5 A away from the 
ATP molecules of actin and heat shock protein structures 
which have almost identical positions. The difference in the 
positions is greater for the adenine rings of the ligands 
(rms deviation is 3.0 A) than for B-phosphates and Mg^^ (the 
deviations are less than 2 A). This result correlates with 
the significant discrepancy between the adenine binding sites 
of glycerol kinase and actin. Adenine of ADP from glycerol 
kinase fits better into the active site of brain hexokinase. 
This agrees with the similarity of the adenine binding sites 
of these enzymes. Mg^* and the phosphates of all 3 
superimposed ATP analogues also satisfactorily fit the model. 
However, all superimposed ATP analogues have Thr863 
overlapping with ribose. In all phosphortransferases except 
hexokinases, this position in the sequences is represented by 
a conserved glycine (Bork et al., 1992). The bad fit of 
ribose suggests that either brain hexokinase changes the 
orientation of Thr863 upon the binding of ATP, or that ATP in 
hexokinases has a slightly different conformation than in the 
other enzymes. 
The energy minimization of ATP in the active site of 
brain hexokinase removed the bad contact without a 
significant change in the position of the ligand. We used ATP 
and from superimposed actin as a starting model for the 
ligands. After the energy minimization, adenine of ATP 
shifted to a position close to that of adenine from the 
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Fig. 3.4. Stereoview of the ATP binding site of brain 
hexokinase(closed form) with ATP analogues superimposed from 
different crystal structures. The backbone of the enzyme is 
represented by smoothed coils. The side chains of 
conservative residues are drawn as ball-and-sticks. Glucose 
is shown in black. (A) labels adenine of 8-bromoadenosine 
monophosphate from the crystal structure of yeast hexokinase 
B(Shoham & Steitz, 1980). (B) labels ADP and Mg^^Cfilled 
circle) from glycerol kinase(Hurley et al., 1993). (C) 
labels ATP and Ca^^(open circle)from actin(Kabsch et al., 
1990). The figure was prepared with MOLSCRIPT(Kraulis, 
1991). 
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glycerol kinase structure. However, the yphosphate resumed 
its initial position. The test minimization of the complex, 
with ADP and from glycerol kinase as a starting model 
gave similar results. 
The energy minimized model of the active site of the 
enzyme with bound glucose, ATP and Mg^^ is presented in Fig. 
3.5. The ATP molecule is positioned in the cleft between two 
lobes of the enzyme. Adenine is bound to the big lobe and 
occupies a cavity between helix a9 (residues 784-788) and the 
loop, connecting strand 612 and helix al2 (residues 863-869). 
Ribose is bound between side chains of Glu 783 and Thr 863. 
The loop residues 863-869 have a similar function in all 
homologous phosphotransferases, i.e.. they form the basis of 
the adenosine-binding site. According to our modeling, one 
face of adenine is exposed to the solvent. This is quite 
different from other structurally known phosphotransferases. 
It is possible that upon the binding of ATP, hexokinase 
undergoes further conformational change, leading it to a more 
closed conformation (Kabsch & Holmes, 1995). 
The phosphate binding site consists of residues from two 
lobes or the catalytic domain of brain hexokinase. At one 
side, phosphates interact with residues 680 and 681 of the B-
turn between strands 6-9 and 6-10, and at the other side, 
they interact with the loop connecting strands 6-2 and 6-3. 
Both elements are conserved within all homologous 
phosphotransferases (Bork et al., 1992; Kabsch et al., 1990; 
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Fig. 3.5. Stereodrawing of the ATP-binding site of the 
model of the ternary complex of brain hexokinase. Glucose 
and ATP are drawn in ball-and-stick, the filled balls are N, 
O, or Mg^"^ atoms. The protein part of the complex is drawn 
with thin lines(except side chains of Asp532 and Asp657). 
The hydrogen bonds and salt linkages between the protein and 
ligands are shown as dash lines. The figure was prepared 
with MOLSCRIPT(Kraulis, 1991). 
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Flaherty et al., 1991). The e-amino group of Lys621 is 4.6 A 
from the y-phosphate. The modeling suggests that this residue 
can be involved in ATP binding. 
In our model Mg^" is coordinated by OIB of the 
B-phosphate, and 03G of the y-phosphate of ATP and it is 
positioned relatively close to Asp532. The model suggests 
that Asp532 coordinates Vlg^* either by direct ionic 
interactions or through a mediating water molecule. This 
finding supports the hypothesis (Wilbands et al., 1994; 
Flaherty et al., 1994) that the catalytic role of this 
aspartate in phosphotransferases is to stabilize the correct 
position of y-phosphate through its interaction with Mg^^. 
Our modeling of ATP bound to the closed form of 
hexokinase supports the suggestion of Steitz and 
collaborations that the correct binding of the 
tripolyphosphate part of ATP requires the closed form of 
hexokinase (Shoham & Steitz, 1980). The positions of all 
three superimposed ATP analogues, being in a good agreement 
with each other, noticeably differ from that of 
8-bromoadenosine monophosphate in the crystal structure of 
open yeast hexokinase (Fig. 3.4). The y-phosphate of ATP in 
the crystallographically determined complex corresponds to 
a-phosphate in our model and is about 6 A away from the 06 
hydroxyl of glucose. A y-phosphate of ATP in our model has a 
more realistic distance from 06 of glucose equal to 3.9 A. 
Assuming that the two models represent the interaction of ATP 
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with open and closed forms of hexokinase, respectively, we 
can conclude that interactions between the phosphate part of 
ATP and hexokinase are responsible for the formation of the 
productive ATP-hexokinase complex, and that the phosphate 
binding site of hexokinase is not formed correctly in the 
open form of the enzyme. 
The model also explains our previous finding (Zeng & 
Fromm, 1995) that shows the importance of Arg539 for 
catalysis. Arg539 interacts with a- and 6-phosphate groups 
of ATP and may stabilize the transition state. In order to 
test the predictions of the model, another two residues 
within different loci of the ATP binding site were mutated. 
Site-directed Mutagenesis of ASP532 in the Putative ATP-
bindina Site—Based on our model of the ATP binding site of 
human brain hexokinase, Asp532 might be involved in binding 
of the Mg^^ ion in the MgATP^" complex. To test this 
hypothesis, Asp532 was mutated to Lys and Glu. The kinetic 
parameters for the mutants, Asp532Lys and Asp532Glu, and the 
wild-type enzyme, were determined and are shown in Table 3.1. 
The mutants, Asp532Lys and Asp532Glu, showed only small 
changes in K, values for glucose and ATP, compared with the 
wild-type enzyme. However, the k^^t values of the mutants, 
Asp532Lys and Asp532Glu, exhibited 1000-fold and 200-fold 
decreases relative to the wild-type enzyme, respectively. The 
mutant Asp532Lys was inhibited by the glucose-6-P analogue 
l,5-an-G6P, with the same Kj values as that of the wild-type 
Table 3.1. A Comparison of the kinetic data of the wild-type and the mutant forms of 
hexokinase 
K„(G1U) K„(ATP) K5(l,5-An-G6P) 
Hexokinase 
(/IM) (mM) (MM) (s-1) 
wild-type 56 + 5.6 1.0 ± 0.2 26 ± 4.8 26.9 
Gly534Ala 287 + 22.2 2.2 + 0.13 82 + 16.5 0.0063 
Gly679Ala 42 ± 6.4 0.23 + 0.39 27 + 6.0 19.3 
Arg539Lys 52 + 0.39 0.43 + 0.11 19 + 4.4 2.2 
Tyr686His 43 ± 4.1 0.35 ± 0.06 9 + 0.8 35.5 
The values shown are the mean ± SME of at least two separate determinations. The 
kinetics analysis was done with the computer program "Kinetics". 
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enzyme. Pi reversed the inhibition. The dramatic decreases 
in activities of hexokinase mutants Asp532Lys and Asp532Glu, 
illustrates the importance of Asp532 for the catalytic 
reaction of human brain hexokinase. Based on our model we can 
suggest two ways that Asp532 may be involved in catalysis: 
(1) its negative charge may be necessary for the formation of 
the correct electrostatic environment in the active site, (2) 
the interaction between Asp532 and the Mg^^ ion may stabilize 
the y-phosphate of ATP in the vicinity of 06-hydroxyl of 
glucose. The recent report of Baijal and Wilson (Baijal & 
Wilson, 1995) that Asp532Asn has significantly reduced 
activity indicates that, indeed, the charge on this group is 
important for catalysis. Our results, support the importance 
of the negative charge at position 532, but also demonstrate 
that the size of the charged group is important as well. 
In heat shock protein, hsc70, the residue corresponding 
to Asp532 of human brain hexokinase is Aspll, whereas in 
actin it is AsplO. Flaherty et al. (Wilbands et al., 1994; 
Flaherty et al., 1994) mutated AsplO to Asn and Ser. The k^^^ 
values decreased to about 1% of the wild-type enzyme, whereas 
the K„ value for ATP increased more than ten-fold. In the 
crystal structure of hsc70, the carboxyl group of AsplO 
ligates to the hydrated Mg^*. The kinetic data of mutants 
AsplOAsn and AsplOSer as well as other mutants suggest that 
the ability of the Mg^^ ion to position the Y~Phosphate for 
nucleophilic attack is critical. The conclusions of these 
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investigators is similar to that which we arrived at for the 
function of Asp532 in human brain hexokinase. 
The K„ values for ATP for the mutants Asp532LYs and 
Asp532Glu hexokinase are the same as for the wild-type 
enzyme, indicating the interaction between Asp532 and the 
Mg^"^ ion of the MgATP^' complex is not responsible for ATP 
binding affinity. Our previous results (Rudolph & Fromm, 
1971; Kosow & Ross, 1970) indicate the Kj value for the ATP"" 
is about the same as the K„ value for MgATP^", a finding 
consistent with our present result. 
The fact that the kcat values decreased signi^icaBtly for 
mutants Asp532Lys, and Asp532Glu relative to wild-type 
hexokinase, whereas the K„ values remain relatively constant, 
suggests that the major effect of these mutations occurs in 
the conversion of the enzyme-Mg^'^ATP-glucose complex to the 
analogous product ternary complex, i.e., in the transition 
state. This conclusion is alluded to based on the kinetic 
mechanism for brain hexokinase which is rapid-equilibrium 
random bi bi (Ning et al., 1969). In this kinetic mechanism 
the breakdown of the enzyme-Mg^^ATP-glucose complex to 
enzyme-Mg^*-ADP-glucose-6-P is rate limiting, and k^at is a 
reflection of the nature of the transition state, but not its 
structure. 
Site-directed Mutagenesis of Thr680—Our model of the 
ATP-binding site of human brain hexokinase predicted that the 
hydroxyl group of Thr680 may form hydrogen bonds to y-
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phosphoryl group of ATP (Fig. 3.6) and thus may be important 
for the catalytic reaction of hexokinase. Therefore, Thr680 
was mutated to Ser and Val. Although the K„ values of both 
mutants for either glucose or ATP showed only slight or no 
change, the values for Thr680Val and Thr680Ser mutants 
exhibited 2000-fold and 2.5-fold decreases, respectively 
(Table 3.1). Since CD spectra for Thr680Val and Thr680Ser 
showed no difference relative to that of the wild-type 
enzyme, we suggest that no secondary conformation change 
occurs after mutagenesis. The dramatic decrease in the ke«t 
value with no change in the K„ values for glucose and ATP 
suggests that the Thr680 is important for catalysis rather 
for binding of ATP. If the proposed interaction between 
Thr680 and OIG of y-phosphate is correct, then this 
interaction may be involved in stabilization of the 
transition state of the reaction. Moreover, the function of 
Thr680 may be similar to that proposed for Asp532, namely, it 
may participate in the stabilization of the vpliosphate in 
the vicinity of 06-hydroxyl group of glucose. 
It was found (Pilkis et al., 1994) that mutations in the 
human glucokinase gene are a common cause of an autosomal 
dominant form of non-insulin-dependent (type 2) diabetes 
mellitus. One mutant, Thr228Met, causes about a 2500-fold 
decrease in the k<,at value but no change in the K„ values 
either for glucose or for ATP relative to the wild-type 
glucokinase. Thr228 corresponds to Thr680 in human brain 
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Fig. 3.6. Schematic drawing of interactions of brain 
hexokinase with ATP, as predicted by modeling. 
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hexokinase. The kinetic properties of Thr228Met mutant is 
similar to those of the Thr680Val mutant in human brain 
hexokinase. Assuming human glucokinase has the same ATP-
binding site as that of human brain hexokinase, Thr228 may 
interact with the ATP in the same way as Thr680 does. 
The kinetic studies of mutants of residues Asp532, 
Thr680, and Arg539 of human brain hexokinase, which according 
to our modeling are involved in binding of tripolyphosphate 
portion of ATP, indicate that these residues are important 
for the catalysis. These results provide strong support for 
the method of modeling the ternary complex of hexokinase with 
ATP and glucose presented in this report. All studied 
mutants have one common and intriguing feature, namely: in 
spite of the involvement of these residues in binding of ATP, 
their mutation significantly reduces only enzyme activity but 
does not alter ATP affinity. The modeling suggests that all 
these residues may be involved in the stabilization of the 
position of y-phosphate of ATP in the vicinity of 06 of 
glucose. Thus, the energy of binding of the phosphate part 
of ATP is presumably used to promote the transition state, 
while the energy of ATP binding comes from nonspecific 
interactions such as the entropy changes during the 
substitution of water molecules from the active site. 
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CHAPTER 4. A STUDY OF THE ATP-BINDING SITE OF HUHAN BRAIN 
HEXOKINASE^ 
A paper to be submitted to the Arch. Biochem. Biophysics. 
Chenbo Zeng^, Guanjun Chen and Herbert J. Fromm^'^ 
Abstract 
The ATP-binding site of human brain hexokinase has been 
modelled and confirmed by site-directed mutagenesis. Several 
residues located in the proposed ATP-binding site are studied 
in the present paper. Four mutants were prepared: Gly534Ala, 
Gly679Ala, Arg539Lys and Tyr686His. The values for the 
Gly534Ala and Arg539Lys mutants decreased 4600-fold and 12-
fold, respectively, whereas the k„t values for the Gly679Ala 
and Tyr686His remained about the same as that of the wild-
type enzyme. The K„ values for either glucose or ATP did not 
show dramatic changes for any of the four mutants relative to 
the wild-type enzyme. All the mutants can be inhibited by 
glucose-6-P with the values similar to the wild-type 
'^This researach was supported in part by Research Grants 
NS10546 from the National Institue of Health, United State Public 
Health Service, and Grant MCB-9218763 from the National Science 
Foundation. 
^Graduate student and Professor, respectively. Department of 
Biochemistry and Biophysics, Iowa State University. Research 
conducted and manuscript written by Zeng with assistance from Chen 
and Fromm. 
^To whom crrespondence should be addressed. 
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enzyme, and the inhibition can be released by inorganic 
phosphate. The circular dichroism and fluorescence spectra 
did not show significant changes for the mutants compared 
with the wild-type enzyme. Heat stability experiment showed 
that only Tyr686His is less thermostable than the wild-type 
enzyme. Based on our molecular model of the ATP-binding 
site, the small side chain of Gly534 interacts with ATP and 
is essential to make appropriate room for binding ATP. Arg539 
binds to the a- and 6- phosphate groups of ATP. We suggest 
that the positive charge of Arg539 is important by 
stabilizing the transition state of the enzyme. The small 
side chain of Gly679 may be important for the correct folding 
of hexokinase. Tyr686 appears to be responsible for 
thermostability. 
Introduction 
Hexokinase I, brain hexokinase, is one of four 
hexokinase isozymes found in mammalian tissue(l). It 
catalyzes the phosphorylation of glucose using ATP as a 
phosphate donor. It is the first rate-limiting reaction of 
the glycolytic pathway in brain tissue and the red blood 
cell(2,3). Brain hexokinase exhibits a unique regulatory 
properties, i.e., it is potently inhibited by its reaction 
product glucose-6-P relative to the other hexokinase 
isozymes, and this inhibition can be reversed by 
physiological levels of inorganic orthophosphate(Pi)(4-6). 
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Hexokinase isoforms I, II, and III exist as a monomer with 
molecular weights of approximately 100,000 and show 
similarity in amino acid sequence(7). Hexokinase isoform IV, 
glucokinase, has a molecular weight of 50,000, similar to 
that of yeast hexokinase. Moreover, isozymes I, II and III 
contain N-terminal and C-terminal domains in which the 
domains exhibit similar amino acid sequences to each other 
and to glucokinase and yeast hexokinase, probably as a result 
of gene duplication and fusion. For isozyme I, the C-
terminal domain possesses the catalytic activity, and the N-
terminal domain is believed to relate to the regulatory 
function(8). On the other hand, in the case of muscle 
hexokinase, isozyme II, both the C-terminal and N-terminal 
domains exhibit comparable catalytic activity(9,10), i.e. . 
there are two active sites per monomer. 
The crystal structure of yeast hexokinase a and b has 
been available for a number of years(11-13). Mammalian 
glucokinase and its glucose binding site has been 
modelled(14). The C-terminal domain of human brain 
hexokinase and its ATP binding site has also been modelled 
Based on the similarities among the ATP-binding domains of 
actin, heat shock protein and glycerol kinase(15). The ATP 
binding site model predicted several amino acid residues( 
Thr680, Asp532 and Arg539) interacting with the ATP and site-
directed mutagenesis was performed to confirm the 
model(15,16). In the present study, we examined some other 
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residues that are thought to be located in the putative ATP 
binding site. 
Experimental Prodedures 
Materials—Affi-Gel Blue Gel and Bio-gel hydroxyapatite 
were obtained from Bio-Rad Laboratories. The Transformer™ 
Site-Directed Mutagenesis Kit(2nd version) was a product of 
Clontech. The Magic Minipreps DNA purification system was a 
product of Promega. Oligonucleotide synthesis and nucleotide 
sequence analysis were done by the Iowa State University 
Nucleic Acid Facility. Nru I was from New England Biolabs. 
Xho I was from Promega. The pET-lla plasmid was obtained 
from Novagen. Escherichia coli strains BL21(DE3) and TG-1 
cells were obtained from Amersham Corp. E. coli strain ZSC13 
is from the Genetic Stock Center, Yale University. 
Ampicillin, phenylmethylsulfonyl fluoride(PMSF)*, ATP, NADP, 
NADPH, glucose-l,6bisphosphate(Glu-l,6-BP), deoxyribonuclease 
I(DNase I), Isopropyl-l-thio-B-D-galactopyranoside(IPTG), and 
1,5-anhydro-D-sorbitol were products of Sigma. 
Expression of Human Brain Hexokinase—The cDNA for human 
brain hexokinase I has been cloned into the expression vector 
pET-lla to generate pET-lla-HKI in our lab(17). pET-lla-HKI 
was transformed into E.coli strain ZSC13, which does not 
*The abbreviations used are; PMSF, phenylmethyl 
sulfonylfluoride; IPTG, Isopropyl-B-D-thiogalactopyranoside; Glu 
1,6-BP, Glu-l,6-bisphosphate; Glucose-6-P,glucose-6-phosphate; 1,5 
an-G6P, 1,5-anhydroglucitol-6-phosphate. 
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contain endogenous hexokinase. lOO-itiL of preculture of the 
transformed E. coli strain in LB medium plus 40mg/L 
ampicillin was grown overnight and then added to 10 liter of 
the same medium. The culture was grown in a fermentor at 
37°C to early log phase(A6oo=0.4), and IPTG was then added to 
a final concentration of 0.4 mM to induce the T7 RNA 
polymerase gene. The culture was grown at a stirring speed 
of 200 epm and 5 psi of filtered air flow for 24 hours at 
22°C. 
Purification of Wild-tpye and Mutant Brain Hexokinase—The 
wild-type and mutant forms of hexokinase were purified as 
described elsewhere(16). 
Site-directed Mutagenesis—Mutagenesis was performed by 
following the instructions provided with the Tansformer™ 
Site-Directed Mutagenesis Kit(2nd version) from Clontech. 
The oligonucleotides used for mutagenesis are as follows: 
5'-CTGGATCTTGCAGGAACC-3' for Gly534Ala, 5'-
CTCATTGTTGCGACCGGC-3' for Gly679Ala, 5'-ACCAATTTCMAGTGCTG-3' 
for Arg539Lys, and 5^-CAATGCCTGCCACATGGAGG-3 ^ for Tyr686His, 
where the underlines represent the mutated bases. The 
selective oligonucleotide sequence was chosen at the Nrul 
restriction site in the vector pET-lla and designed to change 
the Nrul site to a Xhol site. The sequence of the selective 
oligonucleotide is 5'-CAGCCTCGCCTCGAGAACGCCAG-3'. where the 
underline represents the Xhol site. The DNA sequence of the 
mutated gene was verified by DNA sequencing using the method 
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of fluorescent dideoxychain termination sequencing. 
Hexokinase Assay—Hexokinase activity was determined 
spectrophotometrically as described previously(17). 
Preparation of 1.5-an-G6P—1.5-an-G6P was prepared as 
described previously(18). 
Determination of Protein Concentration—Protein 
concentration was determined by the method of Bradford(19), 
using bovine serum albumin as a standard. 
Circular Dichroism Measurement—Circular Dichroism (CD) 
spectra were recorded using a Jasco J710 CD spectrometer as 
descrilied elsewhere (16). 
Thermostability Experiment—The wild-type and mutant 
enzymes were dialyzed against 20 mM of Hepes, containing 1 mM 
mercaptoetnanol. The enzyme concentration was adjusted to 
0.25 mg/mL. The enzyme sample was incubated for 5 minutes at 
different temperatures and the residual activity measured. 
Fluorescence Emission Spectra—The wild-type and mutant 
enzymes were dialyzed against 20 mM of Hepes buffer(pH 7.0), 
containing 1 mM of mercaptoethanol. The enzyme concentration 
was adjusted to 50 nq/mL. Excitation wavelength is 290 nm. 
The fluorescent intensity is recorded in the wavelength range 
from 300 nm to 350 nm. 
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Results 
Purification of the Wild-type and Mutant Human Brain 
Hexokinase—The purification procedure for brain hexokinase is 
described in the literature(17). Two methods were modified. 
1) E. coli strain ZSC13 was used as the overexpression cell. 
E. coli strain ZSC13 is deficient in endogenous hexokinase. 
Therefore, contamination by endogenous enzyme activity can be 
avoided. The contamination by endogenous enzyme activity 
becomes a serious problem when the mutants exhibit low 
hexokinase activity. 2) The fermentor was used to grow cells 
and the purification was scaled up. 70 mg of pure enzyme can 
be obtained from 20 liter of E. coli cells. Fig. 4.1. shows 
the SDS PAGE obtained with the wild-type and mutant 
hexokinases. 
Kinetic Studies of the Wild-type and Mutant 
Hexokinases-The wild-type and mutant enzymes were studied by 
initial rate kinetics and the kinetic parameters are shown in 
the Table 4.1. Gly534 is a conserved residue in actin, heat 
shock proteins and sugar kinases, all of which have a common 
ATP binding domain(20-23). Gly534 is in proximity to ATP in 
our ATP binding site model. To test the role of Gly534, 
Gly534 is mutated to Ala. Compared to the wild-type enzyme, 
the Gly534Ala mutant showed a 4000-fold decreases in its k^at 
value, a 5-fold increase in its K, value for glucose, a 2-
fold increase in its K, value for ATP, and a 3-fold increase 
in its Ki value for glucose-6-P. These kinetic data suggest 
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Fig. 4.1. SDS PAGE patterns for the wild-type and 
mutant human brain hexokinase. Lane 2, wild-type, lane 3, 
Gly534Ala, lane 4, Gly679Ala, lane 5, Arg539Lys, lane 6, 
Tyr686His, Lanes 1 and 7, protein standards; the molecular 
masses for the bands a, b, c, d, and e are 200, 116, 97.4, 
66.2, and 45 kDa, respectively. 
Table 4.1. A Comparison of the Kinetic data of the wild-type 
and the mutant forms of hexokinase 
Hexokinase 
K.(Glu) K„(ATP) K, (l,5-An-G6P) 
(MM) (mM) (MM) (s-1) 
wild-type 56 ± 5.6 1.0 ± 0.2 26 ± 4.8 26.9 
Gly534Ala 287 ± 22.2 2.2 ± 0.13 82 ± 16.5 0.0063 
Gly679Ala 42 ± 6.4 0.23 ± 0.39 27 ± 6.0 19.3 
Arg539Lys 52 ± 0.39 0.43 ± 0.11 19 ± 4.4 2.2 
Tyr686His 43 ±4.1 0.35 ± 0.06 9 ± 0.8 35.5 
The values shown are the mean ± SEM of at least two separate determinations. The 
kinetic analysis was done with the computer program "Kinetics". 
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that the small side chain of Gly534 is essential for 
catalysis but it has no significant effect on substrate and 
inhibitor binding. Another conserved residue, Gly679 is also 
close to ATP in our ATP binding site model(15). When Gly679 
is mutated to Ala, all the kinetic parameters remained about 
the same as that of the wild-type enzyme. That means that 
Gly679 is not essential either for catalysis or binding of 
substrates and the inhibitor, glucose-6-P. Arg539, another 
ATP-binding site residue, was mutated to Lys. The Arg539Lys 
mutant exhibited a 12-fold decrease in its value; 
however, little change with xespect to the other kiTietic 
parameters was observed. When Tyr686 was mutated to His, the 
koat value and K, values for both glucose and ATP were the 
same as those of the wild-type enzyme. These kinetic data 
suggest that Tyr686 is not essential for catalysis ot 
substrate binding. All the wild-type and mutant forms of 
hexokinase are inhibited by glucose-6-P and the inhibition 
can be relieved by inorganic phosphate(Pi). These results 
suggest that the mutated residues are not important for Pi 
regulation. 
Effect of Mutations on the CD Spectra—To determine if the 
mutations affected the secondary structure of human brain 
hexokinase, CD spectra was recorded for the wild-type and the 
four mutant enzymes, Gly534Ala, Gly679Ala, Arg539Lys, and 
Tyr686His. The CD spectra were essentially superimposable 
for the mutant and wild-type enzymes(data not presented). 
75 
5 
'//y 
4 
3 
i/f I 
2 
1 
Gly534Aia 
Gly679Ala 
Arg539Lys 
0 
340 330 320 310 300 
wavelength(nm) 
Fig. 4.2. Fluorescent emission spectra for wild-type 
and mutant forms of human brain hexokinase. 
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suggesting that the mutations did not cause global secondary 
structural changes. 
Effect of Mutations on the Fluorescent Emission 
Spectra—The fluorescent emission spectra were recorded for 
the wild-type and all the four hexokinase mutants(Fig. 4.2.). 
The Tyr686His mutant spectrum showed some change, suggesting 
a structural alteration. The other mutants, Gly534Ala, 
Gly679Ala and Arg539Lys exhibited little change relative to 
the spectrum of the wild-type enzyme, suggesting that no 
conformation change occurs that might perturb the tryptophan 
fluorescence. 
Thermostability Experiment—The wild-type and mutant 
proteins were incubated at different temperatures for 5 
minutes. The residual activity was determined and the result 
are shown in Fig. 4.3. Only the Tyr686His mutant showed 
lower thermostability. The other three mutants showed the 
similar thermostabilities similar to that of the wild-type 
enzyme. 
Discussion 
Fig. 4.4. illustrates the location of the residues that 
were mutated in the putative ATP binding site(15). Gly534 is 
only 3.25 A from the oxygen atom of the 6-phosphoryl group of 
ATP. In the Gly534Ala mutant, the hydrogen atom is replaced 
with the methyl group of Ala. This methyl group interacts 
sterically with the ATP molecule, causing the large decrease 
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temperature (°C) 
Fig. 4.3. Thermostability of the wild-type and mutant 
forms of human brain hexokinase. (•)/Wild-type enzyme; 
(0),Gly679Ala; (a),Arg539Lys; (•)/ Tyr686His. 
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Fig. 4.4. Stereodrawing of the ATP-binding site of the 
model of the ternary complex of brain hexokinase. 
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in catalytic activity but minor changes in the K„ values of 
glucose and ATP and the value for glucose-6-P. Another 
residue Gly679 is 4.25 A from the oxygen atom of a-phosphoryl 
group of the ATP molecule. When the hydrogen side chain of 
Gly679 was replaced with the methyl group of Ala, the 
value for ATP decreased 4-fold while the other kinetic 
properties remained the same as those of the wild-type 
enzyme. Probably the larger distance between Gly679 and ATP 
permits the substitution of hydrogen by the methyl group 
without disturbing the correct orientation of ATP. The 
Gly679Tle mutant was made previously in our lab, but the 
Gly679Ile mutant was overexpressed in an unsoluble form. 
Probaly the small side chain of G679 is responsible for the 
correcting folding of the enzyme. Arg539 interacts with a-
and 6-phosphoryl groups of ATP in the proposed model, Arg539 
was mutated to Lys to determine the role of the positive 
charge of the guanidium group. The Arg539Lys mutant showed a 
small decrease (12-fold) in the keat value, whereas our 
previous(16) results showed that the Arg539Ile mutant 
exhibited a 114-fold decrease in the k^at value. These 
results suggest that the positive charge of Arg539 is 
important, probably by stabilizing the transition state of 
the reaction. 
It was shown(22) that the oxygen atom of a particular 
water molecule, Wat546 in hsc70, is 3.5A from the y-phosphryl 
group of ATP. Therefore, Wat546 was suggested to attack the 
80 
y-phosphoryl of ATP in the ATPase reaction of hsc70. It was 
also suggested(ll) that the 6-OH of the glucose analogue N-
o-toluolylglucocamine is in proximity to Wat546. In hsc70, 
Wat546 is polarized by Asp206(Hisl61 in actin), leading to 
the suggestion that Asp206 may function as a proton 
acceptor. According to the sequence alignments among actin, 
hsc70 and hexokinases from different species, Tyr686 is a 
residue corresponding to Wat546. In the present study 
Tyr686 was mutated to His. The value of the Tyr686His 
mutant and its K. values mutant for both glucose and ATP 
were about the same as those of the wild-type enzyme 
suggesting that Tyr686 is not essential for catalysis. This 
observation is not surprising because in our model of the 
ATP binding site of human brain hexokinase, Tyr686 is far 
from the active site. However, the Tyr686His mutant is less 
thermostable. The melting temperature is about 10°C lower 
than that of the wild-type enzyme. It is possible that the 
hydrophobic aromatic group of Tyr is important for 
stabilizing the correct conformation of human brain 
hexokinase. 
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CHAPTER 5. CRYSTALLIZATION AND PREa^IMINARY X-RAY ANALYSIS OF 
HUMAN BRAIN HEXOKINASE 
A paper submitted to FEES letters for publication 
Alexander E. Aleshin, Chenbo Zeng^, Herbert J. Fromm, and 
Richard B. Honzatko 
Abstract 
Human brain hexokinase type I, expressed in Escherichia 
coli, has been crystallized from polyethylene glycol 8000 in 
the presence of inorganic phosphate. The crystals are hexag­
onal needles of diameter 0.25 mm, diffracting to a resolu­
tion of 3.5 A on a rotating-anode/area-detector system. The 
crystals belong to the space group P3i21/P3221 with cell 
dimensions a = b = 171.5 A and c = 99.4 A. The specific 
volume of the crystal is 4.2 A^/Da, suggesting an asymmetric 
unit with a single 100 kDa molecule and a solvent content of 
71% by volume or two molecules of hexokinase with a solvent 
content of 41%. The complex of hexokinase with glucose 
crystallizes under similar conditions, giving crystals of 
the same morphology. 
^Purified the enzyme for crystallization 
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Contents 
Hexokinase I (ATP: D-hexose 6-phosphotransferase, EC 
2.7.1.1) is one of four mammalian hexokinase isozymes. It is 
the pacemaker of glycolysis in brain and the red blood cell 
[1,2]. In fact, the human brain uses approximately 50% of 
the total chemical energy expended by the human body, a 
demand met almost entirely by the activity of hexokinase 
type I in the brain [2]. Type I and II isozymes have a 
number of features which distinguish them from other 
mammalian hexokinases and from eucaryotic glucokinases, 
such as yeast hexokinase. Hexokinases type I and type II 
bind to the outer membrane of mitochondria [3] and are 
inhibited strongly by their reaction product glucose-6-
phosphate [1, 4-6]. Hexokinase type I differs from 
hexokinase type II in that the product inhibition can be 
reversed by physiological levels of inorganic phosphate 
[1,4,5]. These properties of hexokinase type I may make it 
a critical regulator of glycolysis in brain tissue and 
erythrocytes [1,2,4,7]. 
Human brain hexokinase is a 100-kDa enzyme, consisting 
of two highly homologous (50% identity) sequence domains. 
Each sequence domain in turn is homologous (30% identity) to 
yeast hexokinase and human glucokinase (hexokinase type IV). 
Presumably, human brain hexokinase evolved from a 50-kDa 
yeast-like enzyme by gene duplication and fusion [8,9]. 
Hexokinase type I, lacking the C-terminal sequence 
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domain(mini-hexokinase), has the same kinetic properties 
toward glucose, ATP, and glucose-6-phosphate as intact brain 
hexokinase type I [10]. Mini-hexokinase, however, exhibits 
inhibition by glucose-6-phosphate, that cannot be reversed 
by phosphate [11,12]. The N-terminal sequence domain is 
inactive, generally being regarded as a modulator of 
activity [10]. Glucose-6-phosphate binds near or at the ATP 
site on the C-terminal sequence domain [1,12], rather than, 
as originally suggested [2,13], to an allosteric site on the 
N-terminal sequence domain. On the basis of kinetics [l], 
the binding site for glucose-6-phosphate is different from 
that of glucose. 
The structure of yeast hexokinase is known [14-16], but 
the Protein Data Bank [17] has only two relevant entries 
with sequences deduced from 2.1 A and 3.5 A electron density 
maps. The binding of glucose to the active site causes a 
12° rotation of one of the structural domains of the yeast 
enzyme, transforming it into an active form [18]. Though 
the structure of yeast hexokinase has been used for modeling 
the glucose and ATP binding sites of brain hexokinase 
[19,20], the yeast enzyme is of little help in understanding 
the regulatory properties of hexokinase type I. 
Furthermore, yeast hexokinase and hexokinase type I exhibit 
significant differences in their interaction 
with glucose-6-phosphate [1]. 
Reported here are the crystallization conditions and 
86 
preliminary X-ray diffraction investigation of human brain 
hexokinase type I. The cloned enzyme was produced in 
Escherichia coli strain BL21(DE3) and purified as described 
earlier [12, 21]. The initial conditions for crystallization 
were discovered by the method of hanging drops, using a 
sparse screening matrix [22]. Crystals grew at room 
temperature under the following conditions: 5 nl of the 
protein solution of concentration 20 mg/ml in 20-40 mM 
sodium phosphate buffer (pH 6.5) was mixed with the same 
amount of a precipitant solution containing 3-5% 
(w/v)polyethylene glycol 8000 (Sigma) and 0.1 M sodium 
cacodylate buffer at pH 6.5. The drops were equilibrated 
against 0.7 ml of the precipitant solution. Long hexagonal 
needles of diameter 0.1-0.3 mm appeared within one week. 
Crystals of similar morphology also appeared under the same 
conditions, but with 10 mM glucose present in the protein 
solution. Taking into account that the constants of 
dissociation for phosphate and glucose are 22 juM [23] and 60 
|iM [12], respectively, we suggest that the first crystal 
form contains bound phosphate and the second one both 
ligands. The addition of glucose did not change the 
morphology of crystals, suggesting that hexokinase type I in 
both complexes may have similar conformations. 
We collected data from crystals of brain hexokinase type 
I, complexed with phosphate, on a Siemens area detector 
mounted on an X-ray generator with a Cu rotating anode. We 
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observed diffraction to a resolution of 3.5 A. Due to 
problems of decay, however, we limited data collection to 
3.8 A resolution. The data set contains 33,375 
observations, 15,449 of which are unique reflections (91% of 
data expected to 3.8 A). Data reduction with XENGEN [24] 
gave R„g equal to 0.07. 
The crystals of hexokinase type I belong to space group 
P3221/P3i21. The unit cell dimensions are a = b = 171.5 A 
and c = 99.4 A. If one protein molecule lies in the 
asymmetric unit, the V„ is 4.2 AVDa and the fractional 
volume occupied by the solvent is 71%. These values are 
almost two-fold greater than the average value observed in 
other protein crystals [25], which raises the possibility of 
two molecules of hexokinase type I in the asymmetric unit 
with a solvent content of 41%. Protein crystals with 
trigonal cells, however, generally have a high content of 
solvent [25]. The susceptibility of the crystal to damage 
by X-rays and its modest diffraction limit, are properties 
consistent with a loosely packed asymmetric unit, containing 
a single enzyme molecule and a high solvent content. 
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Fig. 5.1. Photograph of human brain hexokinase crystal. 
The diameter of the crystal is 0.25 mm. 
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CHAPTER 6. GENERAL CONCLUSIONS 
The experiments and results of this study serve to 
establish an ATP binding site model for human brain 
hexokinase. This is believed to be the first such model for 
mammalian hexokinase. Based on the similarity of the ATP-
binding domains among actin, heat shock protein, glycerol 
kinase and brain hexokinase, the initial positions and 
conformations of MgATP^" complexes in the active site of 
brain hexokinase were obtained by superimposing the conserved 
residues of the ATP binding site of the enzyme on the 
corresponding residues of either actin, heat shock protein or 
glycerol kinase, complexed with ligands. The model was then 
energy minimized. Our model predicts the residues in the ATP 
binding site. Site directed mutagenesis was performed on 
those residues to test our model. Asp532, proposed to bind 
to Mg^"^ which forms bonds with 6- and Y~Pl^osphoryl group of 
ATP, was mutated to Lys and Glu. Arg539, which interacts 
with the a- and 6- phosphoryl groups of ATP, was mutated to 
lie and Lys. Thr680 which interacts with the y-phosphoryl 
group and the oxygen linking the a- and 6-phosphoryl groups 
of ATP, was mutated to Val and Ser. The kinetic parameters 
were determined for the mutants. The k^,,. values decreased 
1000- and 200-fold for the Asp532Lys and Asp532Glu 
mutants,respectively; 114- and 12-fold for the Arg539Ile and 
Arg539Lys mutants, respectively; and 2000- and 2-fold for the 
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Thr680Val and Thr680Ser mutants, respectively. The data show 
that these residues are important for catalysis. We suggest 
that Asp532 keeps the yphosphoryl group in the correct 
position for the attack of 6-hydroxyl group of glucose by 
interacting with Mg^^. We propose that Arg539 stabilizes the 
transition state through the interactions of its guanidium 
group and the a- and B-phosphoryl groups. In addition, we 
suggest that Thr680 keeps the y-phosphoryl group in the 
correct orientation for catalysis and also stabilizes the 
transition state of the reaction by forming hydrogen bonds 
with the Y~phosphoryi group and oxygen which links the a- and 
6-phosphoryl groups. 
Our model also illustrates several conserved glycine 
residues that are located in the ATP binding site: Gly534, 
Gly679, and Gly862. The roles of these glycine residues were 
studied by site-directed mutagenesis. The mutant Gly534Ala 
exhibited a 4000-fold decrease in its k^at value. We suggest 
that the small side chain of Gly534 is important so that 
enough space is available for ATP binding in the correct 
orientation. The Gly679Ala mutant did not show significant 
changes in kinetic parameters, whereas the Gly679Ile mutant 
was overexpressed as an insoluble protein. We suggest that 
Gly 679 is important for the correct folding of the enzyme. 
The Gly862Ala mutant showed very low activity compared to the 
wild-type enzyme, and it did not bind to an Affi-gel Blue-gel 
column, a sign of low binding affinity for ATP. The site-
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directed mutagenesis studies provide strong support for our 
ATP binding site model. 
Currently we are preparing mutant enzymes for the 
residues involved in adenine binding based on our model. We 
expect that some of them may be responsible for ATP binding, 
while others are probably responsible for ATP specificity. 
Crystals of human brain hexokinase complexed with 
inorganic phosphate, glucose, or glucose-6-phosphate were 
obtained. The ternary complex of human brain hexokinase-ADP-
glucose was also crystallized, and X-ray diffracted data have 
been collected. The solution of the three dimensional 
structure is currently being carried out. The establishment 
of the three dimensional structure of human brain hexokinase 
will provide important information on how the substrates, ATP 
and glucose, bind to the enzyme, and how the inhibitor, 
glucose-6-phosphate, and the regulator, inorganic phosphate, 
function. 
Minihexokinase was overexpressed in the E. coli strain 
BL21(DE3) and purified to homogeneity. The kinetic 
parameters were determined for the full-length and mini­
hexokinase. The K, values for ATP and glucose and the k^^t 
values are about the same for both enzymes. Glucose-6-
phosphate is a competitive inhibitor for both enzymes; 
however, the inhibition can be relieved by physiological 
concentration of inorganic phosphate only for full-length 
hexokinase. We suggest that the Pi site either resides in 
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the N-terminal half of hexokinase or requires the N-terminal 
portion of the enzyme. To locate the Pi site, Lys290 in the 
P-loop sequence was mutated to Ala in full-length hexokinase. 
The Lys290Ala mutant did not abolish the enzyme's Pi 
deinhibition ability. Therefore Lys290 is not responsible 
for Pi binding. We plan to do sequential deletion in the N-
terminal portion of the enzyme in order to narrow down the 
the location of the Pi binding site. 
The purification procedure for human brain hexokinase 
was improved, producing lO-fold more protein in half the 
time. The availability of large amounts of the enzyme 
improves the possibility that the enzyme can be crystallized 
and that it can be studied by NMR spectroscopy. 
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